IN THE CLAIMS

Please cancel claim 4 without prejudice to applicants' right to pursue the cancelled subject matter in a later filed divisional or continuation application.

Claims 2, 3, and 17 to 20 were canceled in applicants' April 29, 2003 Amendment filed in response to the December 31, 2002 Office Action.

Please amend claim 6 as follows (deletions are shown in strikethrough).

1. (Previously Amended) A compound of the formula **1**



1

or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:

m is an integer from 0 to 3;

p is an integer from 0 to 4;

each R^1 and R^2 is independently selected from H and C_1-C_6 alkyl;

R^3 is selected from





and



wherein the foregoing R^3 groups are optionally substituted by 1 to 3 R^8 groups;

R^4 is $-(CR^{16}R^{17})_m$-C≡C-$(CR^{16}R^{17})_tR^9$, $-(CR^{16}R^{17})_m$-C=C-$(CR^{16}R^{17})_t$-R^9, -$(CR^{16}R^{17})_m$-C≡C-$(CR^{16}R^{17})_kR^{13}$, $-(CR^{16}R^{17})_m$-C=C-$(CR^{16}R^{17})_kR^{13}$, or -$(CR^{16}R^{17})_tR^9$, wherein the

attachment point to R^9 is through a carbon atom of the R^9 group, each k is an integer from 1 to 3, each t is an integer from 0 to 5, and each m is an integer from 0 to 3;

each R^5 is independently selected from halo, hydroxy, $-NR^1R^2$, C_1-C_6 alkyl, trifluoromethyl, C_1-C_6 alkoxy, trifluoromethoxy, $-NR^6C(O)R^1$, $-C(O)NR^6R^7$, $-SO_2NR^6R^7$, $-NR^6C(O)NR^7R^1$, and $-NR^6C(O)OR^7$;

each R^6, R^{6a} and R^7 is independently selected from H, C_1-C_6 alkyl, $-(CR^1R^2)_t(C_6$-C_{10} aryl), and $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R^6 and R^7 groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, $-NR^1R^2$, trifluoromethyl, trifluoromethoxy, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, hydroxy, and C_1-C_6 alkoxy;

or R^6 and R^7, or R^{6a} and R^7, when attached to the same nitrogen atom, can be taken together to form a 4 to 10 membered heterocyclic ring which may include 1 to 3 additional hetero moieties, in addition to the nitrogen to which said R^6, R^{6a}, and R^7 are attached, selected from N, N(R^1), O, and S, provided two O atoms, two S atoms or an O and S atom are not attached directly to each other;

each R^8 is independently selected from oxo (=O), halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C_1-C_6 alkoxy, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^6C(O)R^7$, $-NR^6SO_2NR^7R^1$, $-NR^6C(O)NR^1R^7$, $-NR^6C(O)OR^7$, $-C(O)NR^6R^7$, $-NR^6R^7$, $-NR^6OR^7$, $-SO_2NR^6R^7$, $-S(O)_j(C_1$-C_6 alkyl) wherein j is an integer from 0 to 2, $-(CR^1R^2)_t(C_6$-C_{10} aryl), $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), $-(CR^1R^2)_qC(O)(CR^1R^2)_t(C_6$-$C_{10}$ aryl), $-(CR^1R^2)_qC(O)(CR^1R^2)_t$(4 to 10 membered heterocyclic), $-(CR^1R^2)_tO(CR^1R^2)_q(C_6$-$C_{10}$ aryl), $-(CR^1R^2)_tO(CR^1R^2)_q$(4 to 10 membered heterocyclic), $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t(C_6$-$C_{10}$ aryl), and $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein j is 0, 1 or 2, q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^8 groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^8 groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^6$, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-NR^6R^7$, $-NR^6OR^7$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR^1R^2)_t(C_6$-C_{10} aryl), and $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5;

R^9 is a non-aromatic mono-cyclic ring, a fused or bridged bicyclic ring, or a spirocyclic ring, wherein said ring contains from 3 to 12 carbon atoms in which from 0 to 3 carbon atoms are optionally replaced with a hetero moiety independently selected from N, O, $S(O)_j$ wherein j is an integer from 0 to 2, and $-NR^1-$, provided that two O atoms, two $S(O)_j$ moieties, an O atom and a $S(O)_j$ moiety, an N atom and an S atom, or an N atom and an O atom are not attached directly to each other within said ring, and wherein the carbon atoms of said ring are optionally substituted with 1 or 2 R^8 groups;

each R^{11} is independently selected from the substituents provided in the definition of R^8, except R^{11} is not oxo(=O);

R^{12} is R^6, $-OR^6$, $-OC(O)R^6$, $-OC(O)NR^6R^7$, $-OCO_2R^6$, $-S(O)_jR^6$, $-S(O)_jNR^6R^7$, $-NR^6R^7$, $-NR^6C(O)R^7$, $-NR^6SO_2R^7$, $-NR^6C(O)NR^{6a}R^7$, $-NR^6SO_2NR^{6a}R^7$, $-NR^6CO_2R^7$, CN, $-C(O)R^6$, or halo, wherein j is an integer from 0 to 2;

R^{13} is $-NR^1R^{14}$ or $-OR^{14}$;

R^{14} is H, R^{15}, $-C(O)R^{15}$, $-SO_2R^{15}$, $-C(O)NR^{15}R^7$, $-SO_2NR^{15}R^7$, or $-CO_2R^{15}$;

R^{15} is R^{18}, $-(CR^1R^2)_t(C_6\text{-}C_{10}$ aryl), $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and the aryl and heterocyclic moieties of the foregoing R^{15} groups are optionally substituted with 1 to 3 R^8 substituents;

each R^{16} and R^{17} is independently selected from H, $C_1\text{-}C_6$ alkyl, and $-CH_2OH$, or R^{16} and R^{17} are taken together as $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$;

R^{18} is $C_1\text{-}C_6$ alkyl wherein each carbon not bound to a N or O atom, or to $S(O)_j$, wherein j is an integer from 0 to 2, is optionally substituted with R^{12};

and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH (methine) group, which is not attached to a halogeno, SO or SO_2 group or to a N, O or S atom, is optionally subsituted with a group selected from hydroxy, halo, $C_1\text{-}C_4$ alkyl, $C_1\text{-}C_4$ alkoxy and $-NR^1R^2$.

2. Canceled

3. Canceled

4. Canceled

5. (Original) A compound according to claim 1 wherein R^3 is pyridin-3-yl optionally substituted by 1 to 3 R^8 groups.

6. (Currently Amended) A compound according to claim 1 wherein the following structural portion of the compound of formula **1**



is selected from the group consisting of

3-Methyl-4-(pyridin-2-yloxy)-phenylamino

3-Chloro-4-(pyridin-2-yloxy)-phenylamino

3-Methoxy-4-(pyridin-2-yloxy)-phenylamino

4-(pyridin-2-yloxy)-phenylamino

2-Methyl-4-(pyridin-2-yloxy)-phenylamino

2-Methoxy-4-(pyridin-2-yloxy)-phenylamine

3-Chloro-4-(6-methyl-pyridin-2-yloxy)-phenylamino

3-Methoxy-4-(6-methyl-pyridin-2-yloxy)-phenylamino

3-Methyl-4-(6-methyl-pyridin-2-yloxy)-phenylamino

2-Methoxy-4-(6-methyl-pyridin-2-yloxy)-phenylamino

2-Methyl-4-(6-methyl-pyridin-2-yloxy)-phenylamino

4-(6-methyl-pyridin-2-yloxy)-phenylamino

3-Methoxy-4-(2-methyl-pyridin-3-yloxy)-phenylamino

3-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino

3-Chloro-4-(2-methyl-pyridin-3-yloxy)-phenylamino

2-Methoxy-4-(2-methyl-pyridin-3-yloxy)-phenylamino

2-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino

4-(2-methyl-pyridin-3-yloxy)-phenylamino

3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino

3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino

3-Methoxy-4-(6-methyl-pyridin-3-yloxy)-phenylamino

2-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino

2-Methoxy-4-(6-methyl-pyridin-3-yloxy)-phenylamino

4-(6-methyl-pyridin-3-yloxy)-phenylamino

3-Methyl-4-(pyridin-3-yloxy)-phenylamino

3-Chloro-4-(pyridin-3-yloxy)-phenylamino

3-Methoxy-4-(pyridin-3-yloxy)-phenylamino

2-Methyl-4-(pyridin-3-yloxy)-phenylamino

2-Methoxy-4-(pyridin-3-yloxy)-phenylamino

4-(pyridin-3-yloxy)-phenylamino

3-Methyl-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino

3-Chloro-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino

3-Methoxy-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino

2-Methyl-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino

2-Methoxy-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino

4-(2-methyl-pyrimidin-5-yloxy)-phenylamino

3-Methyl-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino

3-Chloro-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino

3-Methoxy-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino

2-Methyl-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino

2-Methoxy-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino

4-(4-methyl-pyrimidin-5-yloxy)-phenylamino

3-Methyl-4-(2-methyl-pyridin-4-yloxy)-phenylamino

3-Chloro-4-(2-methyl-pyridin-4-yloxy)-phenylamino

3-Methoxy-4-(2-methyl-pyridin-4-yloxy)-phenylamino

2-Methyl-4-(2-methyl-pyridin-4-yloxy)-phenylamino

2-Methoxy-4-(2-methyl-pyridin-4-yloxy)-phenylamino

4-(2-methyl-pyridin-4-yloxy)-phenylamino

3-Methyl-4-(pyridin-4-yloxy)-phenylamino

3-Chloro-4-(pyridin-4-yloxy)-phenylamino

3-Methoxy-4-(pyridin-4-yloxy)-phenylamino

2-Methyl-4-(pyridin-4-yloxy)-phenylamino

2-Methoxy-4-(pyridin-4-yloxy)-phenylamino

4-(pyridin-4-yloxy)-phenylamino

3-Methyl-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino

3-Methoxy-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino

3-Chloro-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino

2-Methyl-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino

2-Methoxy-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino

4-(2-methyl-pyrimidin-4-yloxy)-phenylamino

3-Methyl-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino

3-Methoxy-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino

3-Chloro-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino

2-Methyl-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino

2-Methoxy-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino

4-(6-methyl-pyrimidin-4-yloxy)-phenylamino

~~3-Methyl-4-(pyrazin-2-yloxy)-phenylamino~~

~~3-Methoxy-4-(pyrazin-2-yloxy)-phenylamino~~

~~3-Chloro-4-(pyrazin-2-yloxy)-phenylamino~~

~~2-Methyl-4-(pyrazin-2-yloxy)-phenylamino~~

~~2-Methoxy-4-(pyrazin-2-yloxy)-phenylamino~~

~~4-(pyrazin-2-yloxy)-phenylamino~~

~~3-Chloro-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~

~~3-Methoxy-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~

~~3-Methyl-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~

~~2-Methoxy-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~

~~2-Methyl-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~

~~4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~

~~3-Chloro-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~

~~3-Methoxy-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~

~~3-Methyl-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~

~~2-Methoxy-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~

~~2-Methyl-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~

~~4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~

~~3-Chloro-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~

~~3-Methoxy-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~

~~3-Methyl-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~

~~2-Methoxy-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~

~~2-Methyl-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~

~~4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~

3-Methyl-4-(pyridazin-3-yloxy)-phenylamino

3-Chloro-4-(pyridazin-3-yloxy)-phenylamino

3-Methoxy-4-(pyridazin-3-yloxy)-phenylamino

2-Methyl-4-(pyridazin-3-yloxy)-phenylamino

2-Methoxy-4-(pyridazin-3-yloxy)-phenylamino

4-(pyridazin-3-yloxy)-phenylamino

3-Methyl-4-(6-methyl-pyridazin-3-yloxy)-phenylamino

3-Chloro-4-(6-methyl-pyridazin-3-yloxy)-phenylamino

3-Methoxy-4-(6-methyl-pyridazin-3-yloxy)-phenylamino

2-Methyl-4-(6-methyl-pyridazin-3-yloxy)-phenylamino

2-Methoxy-4-(6-methyl-pyridazin-3-yloxy)-phenylamino

4-(6-methyl-pyridazin-3-yloxy)-phenylamino

3-Methyl-4-(6-methyl-pyridazin-4-yloxy)-phenylamino

3-Chloro-4-(6-methyl-pyridazin-4-yloxy)-phenylamino

3-Methoxy-4-(6-methyl-pyridazin-4-yloxy)-phenylamino

2-Methyl-4-(6-methyl-pyridazin-4-yloxy)-phenylamino

2-Methoxy-4-(6-methyl-pyridazin-4-yloxy)-phenylamino

4-(6-methyl-pyridazin-4-yloxy)-phenylamino

3-Methyl-4-(3-methyl-pyridazin-4-yloxy)-phenylamino

3-Chloro-4-(3-methyl-pyridazin-4-yloxy)-phenylamino

3-Methoxy-4-(3-methyl-pyridazin-4-yloxy)-phenylamino

2-Methyl-4-(3-methyl-pyridazin-4-yloxy)-phenylamino

2-Methoxy-4-(3-methyl-pyridazin-4-yloxy)-phenylamino

4-(3-methyl-pyridazin-4-yloxy)-phenylamino

3-Methyl-4-(pyridazin-4-yloxy)-phenylamino

3-Chloro-4-(pyridazin-4-yloxy)-phenylamino

3-Methoxy-4-(pyridazin-4-yloxy)-phenylamino

2-Methyl-4-(pyridazin-4-yloxy)-phenylamino

2-Methoxy-4-(pyridazin-4-yloxy)-phenylamino

4-(pyridazin-4-yloxy)-phenylamino

3-Chloro-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino

3-Methoxy-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino

3-Methyl-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino

2-Methoxy-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino

2-Methyl-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino, and

4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino.

7. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_tR^9$, wherein m is an integer from 0 to 3, and t is an integer from 0 to 5.

8. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_tR^9$, wherein m is an integer from 0 to 3, and t is an integer from 0 to 5, wherein R^9 is selected from 3-piperidinyl and 4-piperidinyl each of which is optionally substituted with 1 or 2 R^8 groups.

9. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_t-R^9$, wherein m is an integer from 0 to 3, and t is an integer from 0 to 5.

10. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_t-R^9$, wherein m is an integer from 0 to 3, and t is an integer from 0 to 5, wherein R^9 is selected from 3-piperidinyl and 4-piperidinyl (optionally substituted with 1 or 2 R^8 groups).

11. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$, wherein k is an integer from 1 to 3 and m is an integer from 0 to 3.

12. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$, wherein k is an integer from 1 to 3 and m is an integer from 0 to 3, wherein R^{13} is $-NR^1R^{14}$, wherein R^{14} is selected from $-C(O)R^{15}$, $-SO_2R^{15}$, and $-C(O)NR^{15}R^7$.

13. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_kR^{13}$, wherein k is an integer from 1 to 3 and m is an integer from 0 to 3.

14. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C{=}C-(CR^{16}R^{17})_kR^{13}$, wherein k is an integer from 1 to 3 and m is an integer from 0 to 3, wherein R^{13} is $-NR^1R^{14}$, wherein R^{14} is selected from $-C(O)R^{15}$, $-SO_2R^{15}$, and $-C(O)NR^{15}R^7$.

15. (Original) A compound according to claim 1 wherein R^4 is $-(CR^{16}R^{17})_m-C{\equiv}C-(CR^{16}R^{17})_kR^{13}$ or $-(CR^{16}R^{17})_m-C{=}C-(CR^{16}R^{17})_kR^{13}$, wherein k is an integer from 1 to 3 and m is an integer from 0 to 3, R^{13} is $-NR^1R^{14}$ or $-OR^{14}$, R^{14} is R^{15}, R^{15} is R^{18}, and R^{18} is C_1-C_6 alkyl optionally substituted by $-OR^6$, $-S(O)_jR^6$, $-NR^6R^7$, $-NR^6C(O)R^7$, $-NR^6SO_2R^7$, $-NR^6CO_2R^7$, CN, $-C(O)R^6$, or halo.

16. (Original) A compound according to claim 1 selected from the group consisting of:

(±)-[3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide

(±)-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(3-{4-[3-methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide

[3-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine

[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

2-Fluoro-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

[3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(1-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-ylethynyl}-cyclopropyl)-acetamide;

E-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-2-methoxy-acetamide;

N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

E-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

E-2-Ethoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

1-Ethyl-3-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-urea;

Piperazine-1-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;

(±)-2-Hydroxymethyl-pyrrolidine-1-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;

2-Dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

E-N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-methanesulfonamide;

Isoxazole-5-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;

1-(1,1-Dimethyl-3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-3-ethyl-urea;

and the pharmaceutically acceptable salts, prodrugs and solvates of the foregoing compounds.

17. Canceled

18. Canceled

19. Canceled

20. Canceled

21. (Original) A pharmaceutical composition for the treatment of abnormal cell growth in a mammal comprising an amount of a compound of claim 1 that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier.

The above amendments add no new matter to this application. Applicants respectfully request their entry.